Figure 6. The combination of vilazodone and docetaxel synergistically shrink HCC1954 breast tumor xenografts.

(a) Docetaxel was administered on the first day of the treatment regimen, whereas vilazodone was administered on the first day of the treatment regimen and for 3 consecutive days thereafter. (b) Individually docetaxel and vilazodone reduced tumor growth rate as determined by changes in tumor volume with time, but together the drugs shrank tumors. (c) A week after the end of the treatment regimen the tumor xenograft volumes of mice administered vilazodone, docetaxel or the combination of both drugs were statistically significantly smaller than those administered the vehicle. One-way ANOVA P <0.0001.